摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-chloro-5-fluoroquinoline | 917251-76-4

中文名称
——
中文别名
——
英文名称
8-chloro-5-fluoroquinoline
英文别名
5-Fluoro-8 chloroquinoline;5-Fluoro-8-chloroquinoline
8-chloro-5-fluoroquinoline化学式
CAS
917251-76-4
化学式
C9H5ClFN
mdl
MFCD09907836
分子量
181.597
InChiKey
LBYJRVZCGDZRCP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    12.9
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    8-chloro-5-fluoroquinolineN-碘代丁二酰亚胺 作用下, 以 溶剂黄146 为溶剂, 以28%的产率得到8-chloro-5-fluoro-3-iodoquinoline
    参考文献:
    名称:
    The Synthesis and Biological Evaluation of Quinolyl-piperazinyl Piperidines as Potent Serotonin 5-HT1AAntagonists
    摘要:
    As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SA R studies, driven primarily by in vitro liver microsomal stability assessment, identified compound lob, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.
    DOI:
    10.1021/jm1000908
  • 作为产物:
    描述:
    2-氯-5-氟苯胺甘油硫酸sodium 3-nitrobenzenesulfonatesodium hydroxide 作用下, 以 为溶剂, 反应 2.0h, 生成 8-chloro-5-fluoroquinoline
    参考文献:
    名称:
    Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
    摘要:
    本发明涉及新型哌嗪-哌啶化合物。这些化合物可用作5-HT1A结合剂,特别是作为5-HT1A受体拮抗剂和激动剂。这些化合物在治疗中枢神经系统疾病方面很有用,如认知障碍、焦虑症、抑郁症和性功能障碍。
    公开号:
    US20070027160A1
点击查看最新优质反应信息

文献信息

  • 6-Methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
    申请人:Schmid Jean
    公开号:US20070299083A1
    公开(公告)日:2007-12-27
    The present invention relates to hydrochloric acid salt and crystalline forms of the 5-HT 1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.
    本发明涉及盐酸盐和结晶形式的5-HT1A结合剂6-甲氧基-8-[4-(1-(5-氟基)-喹诺啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉,以及其药物组合物和使用方法。
  • Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
    申请人:Bicksler James J.
    公开号:US20080119481A1
    公开(公告)日:2008-05-22
    The present invention relates to crystalline forms of the 5-HT 1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.
    本发明涉及5-HT1A结合剂6-甲氧基-8-[4-(1-(5-氟)-喹啉-8-基哌啶-4-基)-哌嗪-1-基]-喹啉的晶体形式,以及其制备的制药组合物和使用方法。
  • Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
    申请人:Wyeth LLC
    公开号:US07671056B2
    公开(公告)日:2010-03-02
    The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I′): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I′).
    本发明涉及新型哌嗪-哌啶化合物。这些化合物可用作5-HT1A结合剂,特别是5-HT1A受体拮抗剂和激动剂。这些化合物可用于治疗中枢神经系统疾病,如认知障碍、焦虑症、抑郁症和性功能障碍。本发明涉及式(I')的化合物和药学上可接受的盐,其中R1-R16、Ra、Rb和n在说明书中列出。本发明还涉及包含式(I')的化合物和药学上可接受的盐的制药组合物。
  • WO2007/146116
    申请人:——
    公开号:——
    公开(公告)日:——
  • PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR
    申请人:Wyeth
    公开号:EP1888559A2
    公开(公告)日:2008-02-20
查看更多